Teva Pharmaceutical Industries (NYSE:TEVA) updated its FY19 earnings guidance on Wednesday. The company provided earnings per share guidance of $2.20-2.50 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.38. The company issued revenue guidance of $17.0-17.4 billion, compared to the consensus revenue estimate of $17.16 billion.
Several research analysts have commented on the company. UBS Group downgraded Teva Pharmaceutical Industries from a buy rating to a neutral rating and lowered their target price for the stock from $22.00 to $12.00 in a research note on Tuesday, May 28th. Wolfe Research assumed coverage on Teva Pharmaceutical Industries in a research note on Friday, July 19th. They set a peer perform rating and a $9.00 target price for the company. Royal Bank of Canada reissued a hold rating and set a $10.00 target price on shares of Teva Pharmaceutical Industries in a research note on Thursday. Oppenheimer set a $12.00 target price on Teva Pharmaceutical Industries and gave the stock a buy rating in a research note on Wednesday, June 12th. Finally, Citigroup set a $13.00 target price on Teva Pharmaceutical Industries and gave the stock a buy rating in a research note on Monday, June 17th. Six equities research analysts have rated the stock with a sell rating, fourteen have issued a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of Hold and an average price target of $13.21.
Shares of Teva Pharmaceutical Industries stock traded down $0.27 on Friday, hitting $7.02. The stock had a trading volume of 19,402,224 shares, compared to its average volume of 21,946,406. The company has a 50 day moving average of $8.40. Teva Pharmaceutical Industries has a twelve month low of $6.34 and a twelve month high of $25.96. The company has a quick ratio of 0.62, a current ratio of 0.96 and a debt-to-equity ratio of 1.66. The stock has a market capitalization of $7.41 billion, a price-to-earnings ratio of 2.51, a P/E/G ratio of 0.76 and a beta of 1.64.
Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Wednesday, August 7th. The company reported $0.57 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.55 by $0.02. Teva Pharmaceutical Industries had a positive return on equity of 15.94% and a negative net margin of 21.94%. The company had revenue of $4.34 billion during the quarter, compared to the consensus estimate of $4.25 billion. During the same quarter in the prior year, the firm posted $0.78 earnings per share. The firm’s revenue was down 7.7% compared to the same quarter last year. On average, equities analysts anticipate that Teva Pharmaceutical Industries will post 2.26 earnings per share for the current year.
In other news, Director Sol J. Barer bought 111,000 shares of the firm’s stock in a transaction on Monday, June 3rd. The stock was acquired at an average price of $8.98 per share, with a total value of $996,780.00. Following the transaction, the director now owns 115,942 shares of the company’s stock, valued at approximately $1,041,159.16. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, VP Notaristefani Carlo De sold 16,070 shares of the stock in a transaction that occurred on Monday, May 20th. The shares were sold at an average price of $11.42, for a total transaction of $183,519.40. Following the sale, the vice president now directly owns 49,659 shares of the company’s stock, valued at approximately $567,105.78. The disclosure for this sale can be found here. Corporate insiders own 0.49% of the company’s stock.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Recommended Story: Investing strategies using the yield curve
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.